FDA recalls GLP-1 drug, other injectable medication over sterility concerns

Apothecary Pharma is recalling 23 vials of injectable drugs distributed nationwide because their sterility cannot be guaranteed, according to the Food and Drug Administration.

Dig deeper: The voluntary recall includes 22 vials of compounded tirzepatide, a GLP-1 medication with the same active ingredient as Eli Lilly's Mounjaro and Zepbound, as well as one vial of NAD+ injection.

The FDA classified the recall as Class II on Oct. 8, meaning serious health problems are unlikely.